Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021 is registered in ClinicalTrials.gov with Ashibio Inc as lead sponsor.

NCT NCT06508021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06508021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Lead sponsor
Ashibio Inc
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 25, 2024
Completion date
February 4, 2029
Enrollment
92 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva